Notably, the mobilization and re-activation of NK cells using PD-1 blockade is critically important for therapy of patients with HLAneg tumors (e.g., Hodgkin lymphoma) that are resistant to T cell-mediated therapy. Here, PDCD1 is linked to Hodgkins lymphoma.